AzTrials
AzTrials

ST Elevation Myocardial InfarctionSPEEDYPCINCT05604976

Single Catheter Primary Percutaneous Coronary Intervention Method in Patients With ST Elevation Myocardial Infarction

A study testing Percutaneous coronary intervention in people with ST Elevation Myocardial Infarction, run by Tokai University at 1 site in Japan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to test reducing procedure time of percutaneous coronary intervention (PCI) in ST elevation myocardial infarction by single catheter PCI (SC-PCI) method. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
ST Elevation Myocardial Infarction
What is being tested?
Percutaneous coronary intervention
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
430 participants
Where
1 siteJapan
Study dates
1 Nov 2022to 20 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age of 21 years or older
  • Acute ST-segment elevation myocardial infarction
  • Patients indicated for Primary PCI within 12 hours after onset

Who cannot join

  • Patients with shock requiring insertion of Impella, ECMO or IABP before PCI
  • Patients requiring cardiopulmonary resuscitation due to cardiac arrest
  • Patients requiring temporary pacemaker due to bradycardia
  • Patients undergoing dialysis
  • Patients judged by the attending physician to be inappropriate for registration

Trial locations and contacts

1 site in 1 country.

Japan1 site
  • Tokai University Hospital

    Isehara, Kanagawa, 259-1193

Other trials in Japan

About this study

Official title: To Investigate Whether Single Catheter Primary PCI Method Can Reduce the Time Required for Primary PCI in Cases of ST Elevation Myocardial Infarction.

The goal of this clinical trial is to test reducing procedure time of percutaneous coronary intervention (PCI) in ST elevation myocardial infarction by single catheter PCI (SC-PCI) method. The main question it aims to answer is:

  • [question 1] SC-PCI method is skipping catheter exchange with use of a right and left dual purpose universal guiding catheter Ikari Left curve. Does SC-PCI method reduce PCI procedure time? Participants will be randomly assigned to SC-PCI method or conventional method and emergency PCI is performed.

Researchers will compare time from sheath insertion to first device activation between the SC-PCI method and the conventional method.

Read the detailed description

<<Background>>

Acute ST-segment elevation myocardial infarction is a disease of high acute-phase mortality rate, but the life can be saved by implementing emergency percutaneous coronary intervention (PCI). Its efficacy is higher than that of thrombolytic therapy. Moreover, shortening of total ischemia time reduces the mortality rate and can promote recovery of cardiac function. The total ischemia time can be classified into the time from onset to arrival at hospital and the time from arrival at hospital to recanalization of coronary artery (Door-to-balloon time), and shortening of time in all steps is recommended. Various methods, including the part of transportation to hospital and from arrival at hospital to treatment room, are proposed, but there is no effective method for shortening of procedure time for PCI.

Since the right and left dual-purpose universal guiding catheter can be inserted into both the left and right coronary arteries, the time for replacement of catheter can be shortened. Since IKARI Curve catheter is considered to be the most excellent catheter as the universal guiding catheter, it is considered useful for shortening of reperfusion time in myocardial infarction.

<<Objectives.>>

There are a lot of reports that decreased mortality and improvement of cardiac function are observed by shortening of the time from onset of acute myocardial infarction to recanalization. However, shortening of catheterization time, a part of the time, has not been examined. In 60 patients in a single-center retrospective study performed in Tokai University, the time from arterial puncture to reperfusion was shortened, and the time from arrival at hospital to reperfusion was also shortened. In 1275 patients in a multi-center retrospective study, moreover, the time from arterial puncture to reperfusion was significantly shortened by 4 minutes, and a significant decrease was also observed in the time from arrival at hospital to reperfusion. The Door-to-balloon time at this time was 68±46 minutes in the SC-PCI group and 76±51 minutes by the conventional method. Moreover, the time from insertion of sheath to balloon was 19±14 minutes in the SC-PCI group and 23±14 minutes by the conventional method. In addition, shortening of fluoroscopy time was also observed.

Based on this result, the information shall be collected from prospective multi-center randomized study and analyzed to verify that the right and left dual-purpose guiding catheter is useful for shortening of reperfusion time in myocardial infarction.

<<Methods.>>

Multi-center cooperative prospective interventional study, 2-group comparative study, and randomization <Conventional method> If the patients are allocated to this group, the procedure shall be started with an angiographic catheter.

An angiographic catheter is a catheter classified into a special treatment material, "Angiographic Catheter (General Model) Request Code 738180000," and approved for insurance coverage. The catheters adopted by each institution shall be used.

Coronary angiography shall be performed using an angiographic catheter, and PCI shall be performed by replacing to a guiding catheter. There are methods in which a catheter for angiography on right and left sides is performed, a dual-purpose contrast catheter is used, and one contrast catheter and guiding catheter are used, but any method is acceptable if the procedure is started from an angiographic catheter.

<SC-PCI method> When allocated to this group, the procedure shall be started with a guiding catheter of Ikari L Curve. As the Ikari L Curves approved for insurance coverage in Japan, 52 types exist by catalogue according to the difference in diameter and form, of 6 shafts of 5 companies (attached documents). Any of them shall be used. Thereafter, the right and left coronary angiography shall be performed with one right and left dual-purpose guiding catheter, and then PCI shall be performed.

Even if allocated to any group, Synergy stent shall be used when a stent is placed in coronary artery dilation.

A prospective randomization study shall be performed to reduce the bias. For the Sheath-to-First device activation time, a primary endpoint, a test of superiority shall be performed. For the Door-to-balloon time, a secondary endpoint, a test of non-inferiority shall be performed, and if the non-inferiority is demonstrated, a test of superiority shall also be performed.

The primary endpoint shall be analyzed by Intention-to-treat. The operators who can participate in this study shall take charge of any group, and who are the PCI operators who have used the Ikari L Curve guiding catheter on the right coronary artery in at least 5 patients and left coronary artery in at least 5 patients.

<<Number of Target Patients and Rationales for Setting>>

<Number of target patients> 400 patients in total (200 patients for SC-PCI method, 200 patients for conventional method) <Rationale for setting> In a multicenter retrospective study, the time from insertion of sheath to balloon (S2B) was 19±14 minutes in the SC-PCI group and 23±14 minutes for the conventional method. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 388. Considering 3% dropout cases, registration of a total of 400 patients is planned.

A secondary endpoint, the D2B time was 68±46 minutes in the SC-PCI group and 76±51 minutes for the conventional method as a result of retrospective study. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 1160. Therefore, the power is insufficient to show significance in the analysis of D2B time, and a non-inferiority test shall be performed. The margin of noninferiority is set at 1.3. If the D2B time by the conventional method is 76 minutes, the 1.3 times longer time is 98.8 minutes, and the difference is 22.8 minutes. In the treatment of myocardial infarction, the difference of 23 minutes or more is considered to be inferior from the standpoint of expert, and therefore it was set. Non-inferiority test shall be performed based on the 95% confidence interval (test of two-sided 5% or one-sided 2.5%) of the difference from mean value. If non-inferiority is shown, the test of superiority shall also be performed.

Being tested
Percutaneous coronary intervention
Keywords
Primary percutaneous coronary intervention, Door-to-balloon time, guiding catheter
Medical subject headings
ST Elevation Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous coronary interventionDevice

    Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter

Study groups in NCT05604976
Study groupRoleWhat they receive
SC-PCIExperimentalPrimary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.
Receives: Device: Percutaneous coronary intervention
ConventionalActive comparatorPrimary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.
Receives: Device: Percutaneous coronary intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sheath-to-first device activation time

    Time from insertion of sheath to reperfusion treatment apparatus (First device activation)

    Measured: the end of PCI

Secondary outcomes (10)
  1. Door-to-balloon time

    Time from arrival at hospital to reperfusion treatment apparatus (First device activation)

    Measured: the end of PCI

  2. Total ischemia time

    Time from the onset of myocardial infarction to achievement of TIMI 3 reperfusion

    Measured: the end of PCI

  3. Fluoroscopy time and fluoroscopy dose

    Radiation dose assessed as fluoroscopy time and dose

    Measured: the end of PCI

  4. Amount of contrast medium

    Dose of contrast medium used during PCI procedure

    Measured: the end of PCI

  5. Number of catheters used

    Total number of catheters used during the PCI procedure

    Measured: the end of PCI

  6. Hospital expense

    Total cost required for the total hospital stay

    Measured: 30 days

  7. All-cause mortality and cardiovascular mortality at 30 days

    All-cause mortality and cardiovascular mortality at 30 days

    Measured: At 30 days from the onset of STEMI

  8. Hemorrhagic complication rate at 30 days

    BARC 3 or 5 hemorrhagic complications

    Measured: At 30 days from the onset of STEMI

  9. All-cause mortality and cardiovascular mortality at 1 year

    All-cause mortality and cardiovascular mortality at 1 year

    Measured: 1 year after the randomization

  10. Success rate of SC-PCI method

    Success of SC-PCI method is defined as diagnostic angiography and PCI is performed using a single universal guiding catheter, Ikari left.

    Measured: the end of PCI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2022
  2. Study start1 Nov 2022
  3. Primary completion20 Dec 2024 (estimated)
  4. Study completion20 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Study participants are randomly divided into two groups: one in which Primary PCI is initiated with a universal guiding catheter and the other with a diagnostic catheter. Compare time from sheath insertion to first device activation.
Masking
None (open label)
Enrolment
430 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05604976
Sponsor's protocol ID
SPEEDY PCI
Acronym
SPEEDYPCI
Status last verified
Nov 2023
First submitted
9 Oct 2022
Last updated
13 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: There are no plans to obtain IPD consent from patients.

Publications

  • Lee KH, Torii S, Oguri M, Miyaji T, Kiyooka T, Ono Y, Asada K, Adachi T, Takahashi A, Ikari Y. Reduction of door-to-balloon time in patients with ST-elevation myocardial infarction by single-catheter primary percutaneous coronary intervention method. Catheter Cardiovasc Interv. 2022 Feb;99(2):314-321. doi: 10.1002/ccd.29797. Epub 2021 May 31.

    PubMed 34057275
  • Torii S, Fujii T, Murakami T, Nakazawa G, Ijichi T, Nakano M, Ohno Y, Shinozaki N, Yoshimachi F, Ikari Y. Impact of a single universal guiding catheter on door-to-balloon time in primary transradial coronary intervention for ST segment elevation myocardial infarction. Cardiovasc Interv Ther. 2017 Apr;32(2):114-119. doi: 10.1007/s12928-016-0395-z. Epub 2016 Apr 28.

    PubMed 27125428
  • Youssef AA, Hsieh YK, Cheng CI, Wu CJ. A single transradial guiding catheter for right and left coronary angiography and intervention. EuroIntervention. 2008 Jan;3(4):475-81. doi: 10.4244/eijv3i4a85.

    PubMed 19736091
  • Ikari Y, Masuda N, Matsukage T, Ogata N, Nakazawa G, Tanabe T, Morino Y. Backup force of guiding catheters for the right coronary artery in transfemoral and transradial interventions. J Invasive Cardiol. 2009 Nov;21(11):570-4.

    PubMed 19901410
  • Ikari Y, Nagaoka M, Kim JY, Morino Y, Tanabe T. The physics of guiding catheters for the left coronary artery in transfemoral and transradial interventions. J Invasive Cardiol. 2005 Dec;17(12):636-41.

    PubMed 16327043
  • Ikari Y, Nakajima H, Iijima R, Aoki J, Tanabe K, Nakayama T, Miyazawa A, Hatori M, Kyouno H, Tanimoto S, Amiya E, Nakazawa G, Onuma Y, Hara K. Initial characterization of Ikari Guide catheter for transradial coronary intervention. J Invasive Cardiol. 2004 Feb;16(2):65-8.

    PubMed 14760193
  • Ikari Y, Ochiai M, Hangaishi M, Ohno M, Taguchi J, Hara K, Isshiki T, Tamura T, Yamaguchi T. Novel guide catheter for left coronary intervention via a right upper limb approach. Cathet Cardiovasc Diagn. 1998 Jun;44(2):244-7. doi: 10.1002/(sici)1097-0304(199806)44:23.0.co;2-l.

    PubMed 9637453

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous coronary intervention in people with ST Elevation Myocardial Infarction, run by Tokai University at 1 site in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sheath-to-first device activation time (time frame: the end of PCI). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05604976, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in